Figure 1
The flow of the study sample. SPRINT, Systolic Blood Pressure Intervention Trial; ACCORD-BP, Action to Control Cardiovascular Risk in Diabetes Blood Pressure; NHANES, National Health And Nutrition Examination Survey; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease. The SPRINT trial included 9361 adults without diabetes in the USA. The key inclusion criteria included: age ≥50 years, SBP 130–180 mm Hg at screening and high CVD risk (i.e. the presence of clinical or subclinical CVD, chronic kidney disease, 10-year Framingham risk score ≥15% or age ≥75 years). The ACCORD-BP included 4733 adults with diabetes and glycated haemoglobin levels ≥7.5%. The key inclusion criteria included: age ≥40 years with clinical CVD or age ≥55 years at high CVD risk (atherosclerosis, albuminuria, left ventricular hypertrophy, or ≥2 CVD risk factors (dyslipidaemia, hypertension, smoking or obesity)), SBP 130–180 mm Hg on ≤3 antihypertensive use at screening and urinary protein excretion <1.0 g/day. *Although the eligibility criteria for both trials included SBP 130–180 mm Hg at screening, one-third of participants showed SBP ≤132 mmHg at baseline in both SPRINT and ACCORD-BP.10,11,14 More details are described in Supplementary Figure S1 (available as Supplementary data at IJE online)

The flow of the study sample. SPRINT, Systolic Blood Pressure Intervention Trial; ACCORD-BP, Action to Control Cardiovascular Risk in Diabetes Blood Pressure; NHANES, National Health And Nutrition Examination Survey; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease. The SPRINT trial included 9361 adults without diabetes in the USA. The key inclusion criteria included: age ≥50 years, SBP 130–180 mm Hg at screening and high CVD risk (i.e. the presence of clinical or subclinical CVD, chronic kidney disease, 10-year Framingham risk score ≥15% or age ≥75 years). The ACCORD-BP included 4733 adults with diabetes and glycated haemoglobin levels ≥7.5%. The key inclusion criteria included: age ≥40 years with clinical CVD or age ≥55 years at high CVD risk (atherosclerosis, albuminuria, left ventricular hypertrophy, or ≥2 CVD risk factors (dyslipidaemia, hypertension, smoking or obesity)), SBP 130–180 mm Hg on ≤3 antihypertensive use at screening and urinary protein excretion <1.0 g/day. *Although the eligibility criteria for both trials included SBP 130–180 mm Hg at screening, one-third of participants showed SBP ≤132 mmHg at baseline in both SPRINT and ACCORD-BP.10,11,14 More details are described in Supplementary Figure S1 (available as Supplementary data at IJE online)

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close